D-0264-2022 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-0264-2022 was initiated by Lupin Pharmaceuticals Inc. on Nov 19, 2021 and is designated Class III. Reason for recall: Subpotent Drug The recall status is terminated (terminated Nov 15, 2022). Affected quantity: 4113 cartons.

Recall details

Product Type
Drugs
Report Date
Dec 8, 2021
Initiation Date
Nov 19, 2021
Termination Date
Nov 15, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
4113 cartons

Product description

Tydemy (drospirenone, ethinyl estradiol & levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg), packaged in cartons containing 3 wallets of 28 Tablets each, Rx Only, Distributed by: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United Stated, Manufactured by: Lupin Limited, Pithampur, (M.P.) - 454775, India, 244896, The individual wallet NDC 68180-904-11 and the carton NDC 68180-904-13.

Reason for recall

Subpotent Drug

Distribution pattern

nationwide within the United States

Code information

Lot #: L000784 and L000785, Exp. Date May 2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0264-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0264-2022. Report a data issue: hello@regdatalab.com.